Risk Adapted Therapy Optimization for Patients With Relapsed or Refractory Aggressive Non-Hodgkin-Lymphoma

NCT00384553 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Non-Hodgkin's Lymphoma

Interventions

DRUG: Rituximab
DRUG: DHAP
DRUG: TEC
DRUG: autologous stem cell transplantation

Sponsor

University of Magdeburg